Clinical Trial Detail

NCT ID NCT01441947
Title Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Massachusetts General Hospital
Indications

Her2-receptor negative breast cancer

Therapies

Cabozantinib + Fulvestrant

Age Groups: adult senior

Additional content available in CKB BOOST